Simagchem Corporation | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 13806087780 | |||
![]() |
sale@simagchem.com | |||
Chemical manufacturer since 2002 | ||||
chemBlink standard supplier since 2008 | ||||
BOC Sciences | USA | Inquire | ||
---|---|---|---|---|
![]() |
+1 (631) 485-4226 | |||
![]() |
info@bocsci.com | |||
Chemical manufacturer | ||||
chemBlink standard supplier since 2010 | ||||
Medilink Pharmachem | India | Inquire | ||
---|---|---|---|---|
![]() |
+91 (79) 3007-0133 | |||
![]() |
exports@medilinkpharma.com | |||
Chemical distributor since 1996 | ||||
chemBlink standard supplier since 2014 | ||||
Leap Chem Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (852) 3060-6658 | |||
![]() |
market19@leapchem.com | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2006 | ||||
chemBlink standard supplier since 2015 | ||||
Shanghai Yuanye Bio-Technology Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (21) 6184-5781 +86 13585604150 | |||
![]() |
shyysw053@163.com | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2009 | ||||
chemBlink standard supplier since 2016 | ||||
Guangzhou Green Cross Pharmaceutical Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (20) 8222-0238 | |||
![]() |
wangsy@m-pharma.com.cn | |||
Chemical manufacturer since 1991 | ||||
chemBlink standard supplier since 2024 | ||||
Papchem Lifesciences | India | Inquire | ||
---|---|---|---|---|
![]() |
9061328401 | |||
![]() |
bd@papchemlifesciences.com | |||
Chemical manufacturer since 2021 | ||||
chemBlink standard supplier since 2024 | ||||
Classification | Analytical chemistry >> Analytical reagent >> Ion chromatography reagent |
---|---|
Name | Pamabrom |
Synonyms | 2-Amino-2-methylpropanol 8-bromotheophyllinate |
Molecular Structure | ![]() |
Molecular Formula | C7H7BrN4O2.C4H11NO;C11H18BrN5O3 |
Molecular Weight | 348.20 |
CAS Registry Number | 606-04-2 |
EC Number | 210-103-4 |
SMILES | CC(C)(CO)N.CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Br |
Solubility | 10 mM (DMSO) |
---|---|
Hazard Symbols |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hazard Statements | H302 Details | ||||||||||||
Precautionary Statements | P264-P270-P301+P317-P330-P501 Details | ||||||||||||
Hazard Classification | |||||||||||||
| |||||||||||||
SDS | Available | ||||||||||||
The diuretic pamabrom was discovered in the mid-20th century and has since been widely used in medical treatment. Originally synthesized to treat fluid retention disorders, pamabrom's efficacy lies in its ability to increase urine output without significantly altering electrolyte balance. This property makes it valuable in treating conditions such as menstrual-related edema and some forms of bloating. Pamabrom's mechanism of action involves stimulation of renal tubular function, thereby promoting the excretion of excess fluid and reducing swelling. Unlike some diuretics that can cause potassium deficiency, pamabrom generally maintains electrolyte levels within the normal range, enhancing its safety for short-term therapeutic use. In addition to its medical uses, pamabrom is used in pharmaceutical formulations designed to relieve symptoms of premenstrual syndrome (PMS) and associated menstrual discomfort. Its inclusion in over-the-counter medications highlights its accessibility and widespread acceptance among consumers seeking relief from temporary fluid retention. Research is ongoing to optimize pamabrom's efficacy and explore its potential applications in related therapeutic areas. As the understanding of its pharmacological properties continues to evolve, pamabrom remains a key component in the management of diseases where fluid balance regulation is critical. |
Market Analysis Reports |
List of Reports Available for Pamabrom |